drugset / Trial / NCT03573947
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, non-randomized, phase II clinical research study designed to assess the safety and efficacy of nivolumab and ipilimumab in combination with paclitaxel in patients with treatment naïve NSCLC.
Timeline
- Start
- 2018-10-02
- Primary completion
- 2023-03-12
- Completion
- 2023-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |